The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Achillion Pharmaceuticals Inc. | COM | 00448Q201 | 5,744 | 1,279,340 | SH | DFND | 3 | 1,279,340 | 0 | 0 | |
| Agios Pharmaceuticals Inc. | COM | 00847X104 | 183,562 | 2,749,998 | SH | DFND | 3 | 2,749,998 | 0 | 0 | |
| Alder Biopharmaceuticals Inc. | COM | 014339105 | 27,759 | 2,266,008 | SH | DFND | 3 | 2,266,008 | 0 | 0 | |
| Alexion Pharmaceuticals Inc. | COM | 015351109 | 190,013 | 1,354,428 | SH | DFND | 2 | 1,354,428 | 0 | 0 | |
| Alnylam Pharmaceuticals Inc. | COM | 02043Q107 | 130,571 | 1,111,338 | SH | DFND | 3 | 1,111,338 | 0 | 0 | |
| AveXis, Inc. | COM | 05366U100 | 38,963 | 402,800 | SH | DFND | 3 | 402,800 | 0 | 0 | |
| Celgene Corp | COM | 151020104 | 464,334 | 3,184,298 | SH | DFND | 2 | 3,184,298 | 0 | 0 | |
| Cidara Therapeutics Inc. | COM | 171757107 | 10,816 | 1,335,272 | SH | DFND | 3 | 1,335,272 | 0 | 0 | |
| Esperion Therapeutics Inc. | COM | 29664W105 | 105,150 | 2,097,964 | SH | DFND | 3 | 2,097,964 | 0 | 0 | |
| Five Prime Therapeutics Inc. | COM | 33830X104 | 31,808 | 777,500 | SH | DFND | 3 | 777,500 | 0 | 0 | |
| Gilead Sciences Inc. | COM | 375558103 | 224,798 | 2,774,596 | SH | DFND | 1 | 2,774,596 | 0 | 0 | |
| Halozyme Therapeutics Inc. | COM | 40637H109 | 149,835 | 8,626,051 | SH | DFND | 3 | 8,626,051 | 0 | 0 | |
| Incyte Corp. | COM | 45337C102 | 428,240 | 3,668,322 | SH | DFND | 3 | 3,668,322 | 0 | 0 | |
| Intercept Pharmaceuticals Inc. | COM | 45845P108 | 28,191 | 485,719 | SH | DFND | 3 | 485,719 | 0 | 0 | |
| Intra-Cellular Therapies Inc. | COM | 46116X101 | 34,716 | 2,200,000 | SH | DFND | 3 | 2,200,000 | 0 | 0 | |
| Ionis Pharmaceuticals Inc. | COM | 462222100 | 398,600 | 7,861,934 | SH | DFND | 3 | 7,861,934 | 0 | 0 | |
| Juno Therapeutics Inc. | COM | 48205A109 | 92,187 | 2,055,000 | SH | DFND | 3 | 2,055,000 | 0 | 0 | |
| MacroGenics Inc. | COM | 556099109 | 44,360 | 2,400,412 | SH | DFND | 3 | 2,400,412 | 0 | 0 | |
| Myovant Sciences Ltd. | COM | G637AM102 | 53,803 | 3,477,882 | SH | DFND | 3 | 3,477,882 | 0 | 0 | |
| Neurocrine Biosciences Inc. | COM | 64125C109 | 212,198 | 3,462,753 | SH | DFND | 3 | 3,462,753 | 0 | 0 | |
| Novavax Inc. | COM | 670002104 | 9,496 | 8,330,000 | SH | DFND | 3 | 8,330,000 | 0 | 0 | |
| Prothena Corp. PLC | COM | G72800108 | 22,670 | 350,000 | SH | DFND | 3 | 350,000 | 0 | 0 | |
| Radius Health Inc. | COM | 750469207 | 211,979 | 5,498,799 | SH | DFND | 4 | 5,498,799 | 0 | 0 | |
| Regeneron Pharmaceuticals Inc. | COM | 75886F107 | 91,660 | 205,000 | SH | DFND | 2 | 205,000 | 0 | 0 | |
| Sage Therapeutics Inc. | COM | 78667J108 | 68,059 | 1,092,439 | SH | DFND | 3 | 1,092,439 | 0 | 0 | |
| Tesaro Inc. | COM | 881569107 | 128,609 | 996,193 | SH | DFND | 3 | 996,193 | 0 | 0 | |
| Vertex Pharmaceuticals Inc. | COM | 92532F100 | 224,327 | 1,475,445 | SH | DFND | 3 | 1,475,445 | 0 | 0 | |